Astrocytic ATP13A2 modulates neuroinflammatory responses via mitochondrial fission in Parkinson's disease.
4 affiliations
- 1Department of Pharmacy, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, Jiangsu, China.
- 2College of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu, China.
- 3Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
- 4The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Abstract
Parkinson's disease (PD) is a global health problem that urgently requires deeper mechanistic insights. Mutations in the ATPase cation transporting 13A2 (ATP13A2) gene are linked to autosomal recessive PD, yet the pathological roles of this gene remain incompletely defined. Previous studies on ATP13A2 have focused mainly on its lysosomal functions in neurons, whereas its role in astrocytes has been largely overlooked. Here, we investigated how ATP13A2 affects astrocytic mitochondrial function and contributes to PD pathology. Using PD mice and Atp13a2 knockout mice, we found that loss of Atp13a2 disrupts mitochondrial morphology and dynamics in the substantia nigra, with astrocytes showing both excessive fission and activation. We further found that Atp13a2 deficiency caused excessive mitochondrial fission, elevated reactive oxygen species (ROS) levels, and promoted extracellular double-stranded DNA release. ELISA measurements revealed significantly increased secretion of IL-1β, IL-6, and TNF-α, indicating increased release of pro-inflammatory cytokines. Importantly, both pharmacological inhibition of fission via Mdivi-1 and Atp13a2 overexpression restored mitochondrial dynamics homeostasis, suppressed oxidative stress, and reduced cytokine secretion. Collectively, these findings demonstrate that ATP13A2 preserves the mitochondrial fission-fusion balance in astrocytes; its loss breaks this balance, thereby triggering neuroinflammation. By uncovering previously unrecognized roles of ATP13A2 in regulating mitochondrial fission and subsequent neuroinflammation, this study provides new insights into PD pathogenesis and identifies potential molecular targets for therapy. These findings open fresh avenues for developing more effective strategies to modify PD progression.
Related
- Air pollution is associated with sex‐specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at‐risk individuals
- Correlation Between Gut Microbiota Shifts, Lipopolysaccharide Levels, and Neuroinflammatory Responses Following Ischemic Stroke
- FTO-mediated m6A regulation modulates hepatic stellate cell activation through the IGF2BP1–TRIB3 axis and mitochondrial homeostasis
- Dopamine replacement therapy modulates DDC, prolactin and AOC3 levels in Parkinson’s disease
- Probiotic Spore Inspired Oral Drug Delivery System With Multiple‐Barriers‐Crossing Ability Modulates Gut‐Brain Axis for Parkinson's Disease Therapy
BibTeX
@article{qiao2026astrocytic,
title = {{Astrocytic ATP13A2 modulates neuroinflammatory responses via mitochondrial fission in Parkinson's disease.}},
author = {Chen Qiao and Huajun Mo and Xiangqi Hu and Tao Dang and Fenglan Xu and Dan Yang and Jiang Ni and Linxiao Wang},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1959910},
url = {https://europepmc.org/article/MED/42952843},
note = {CC BY},
}
RIS
TY - JOUR
TI - Astrocytic ATP13A2 modulates neuroinflammatory responses via mitochondrial fission in Parkinson's disease.
AU - Chen Qiao
AU - Huajun Mo
AU - Xiangqi Hu
AU - Tao Dang
AU - Fenglan Xu
AU - Dan Yang
AU - Jiang Ni
AU - Linxiao Wang
PY - 2026
DA - 2026/10/14
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1959910
UR - https://europepmc.org/article/MED/42952843
AB - Parkinson's disease (PD) is a global health problem that urgently requires deeper mechanistic insights. Mutations in the ATPase cation transporting 13A2 (ATP13A2) gene are linked to autosomal recessive PD, yet the pathological roles of this gene remain incompletely defined. Previous studies on ATP13A2 have focused mainly on its lysosomal functions in neurons, whereas its role in astrocytes has been largely overlooked. Here, we investigated how ATP13A2 affects astrocytic mitochondrial function and contributes to PD pathology. Using PD mice and Atp13a2 knockout mice, we found that loss of Atp13a2 disrupts mitochondrial morphology and dynamics in the substantia nigra, with astrocytes showing both excessive fission and activation. We further found that Atp13a2 deficiency caused excessive mitochondrial fission, elevated reactive oxygen species (ROS) levels, and promoted extracellular double-stranded DNA release. ELISA measurements revealed significantly increased secretion of IL-1β, IL-6, and TNF-α, indicating increased release of pro-inflammatory cytokines. Importantly, both pharmacological inhibition of fission via Mdivi-1 and Atp13a2 overexpression restored mitochondrial dynamics homeostasis, suppressed oxidative stress, and reduced cytokine secretion. Collectively, these findings demonstrate that ATP13A2 preserves the mitochondrial fission-fusion balance in astrocytes; its loss breaks this balance, thereby triggering neuroinflammation. By uncovering previously unrecognized roles of ATP13A2 in regulating mitochondrial fission and subsequent neuroinflammation, this study provides new insights into PD pathogenesis and identifies potential molecular targets for therapy. These findings open fresh avenues for developing more effective strategies to modify PD progression.
SN - 2296-634X
ER -